CN103808774B - Mean corpuscular concentration of glucose - Google Patents
Mean corpuscular concentration of glucose Download PDFInfo
- Publication number
- CN103808774B CN103808774B CN201410066276.XA CN201410066276A CN103808774B CN 103808774 B CN103808774 B CN 103808774B CN 201410066276 A CN201410066276 A CN 201410066276A CN 103808774 B CN103808774 B CN 103808774B
- Authority
- CN
- China
- Prior art keywords
- glucose
- concentration
- mean corpuscular
- blood
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 64
- 239000008103 glucose Substances 0.000 title claims abstract description 64
- 239000008280 blood Substances 0.000 claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 34
- 238000005534 hematocrit Methods 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000005259 measurement Methods 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 abstract description 11
- 238000011160 research Methods 0.000 abstract description 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 2
- 238000012937 correction Methods 0.000 abstract description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 19
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Mean corpuscular concentration of glucose, in field of medical examination, does not also have a kind of method that can measure concentration of glucose in red blood cell.This method can by measuring full blood glucose concentration, plasma glucose concentration, hematocrit value three data with a blood sample, and the formulae discovery substituting into this invention goes out mean corpuscular concentration of glucose.Its formula is: mean corpuscular concentration of glucose=[full blood glucose concentration-plasma concentration of glucose × (1-hematocrit value)] ÷ hematocrit value mean corpuscular concentration of glucose, for the correction of portable glucose meter, and the research of insulin resistance has important meaning.
Description
Technical field
in medical testblood glucose sugar determination, can have plasma glucose sugar determination, serum glucose mensuration, full blood glucose mensuration according to the difference of sample used.But the not simple assay method for clinical mean corpuscular concentration of glucose.
Background technology
Along with the incidence of disease of China's diabetes is more and more higher, the mensuration of glucose is more and more important for the diagnosis of diabetes, treatment, research.The mensuration of mean corpuscular concentration of glucose is for the correction of blood glucose meter, and the research of insulin resistance is all very important.This method can calculate mean corpuscular concentration of glucose by plasma glucose concentration, full blood glucose concentration, hematocrit value.
Summary of the invention
first talk aboutwhat is plasma glucose, full blood glucose, hematocrit value.
plasma glucose: gather anticoagulant heparin whole blood, through the concentration of glucose that centrifugal separation plasma measures.
Full blood glucose: the red blood cell in whole blood is all smashed, whole blood becomes pure solution, and then the concentration of glucose measured.
Hematocrit value: refer to that red blood cell accounts for the number percent of whole blood volume.The ratio of its reflection red blood cell and blood plasma.To add the blood of a small amount of anti-coagulants mixing, load specific volume pipe that is special, tool scale, with the centrifugation half an hour of 3000 turns per minute, the each composition of visible blood presses the different and layering of gravity, and upper strata weak yellow liquid is blood plasma, and the opaque kermesinus thrombus of lower floor is red blood cell, skim tunica albuginea between red blood cell and blood plasma is leucocyte and blood platelet, account for 1%, now, red blood cell accounts for whole blood volume percent and is hematocrit value.Because now red blood cell is compressed zero-clearance, also known as packed cell volume.The hematocrit value of health adult of China, man 40 ~ 50%, female 37 ~ 48%.
Instrument
1. German EKF diagnostic companies malaga sugar/lactic acid analysis instrument (this instrument is Enzyme Electrode, and blood plasma, serum, whole blood can be used to measure concentration of glucose for sample)
2. Ultracentrifuge (for centrifugal separation plasma and mensuration hematocrit value).
This method is after utilizing whole blood centrifugal, and whole blood can be divided into two-layer substantially, and upper strata weak yellow liquid is blood plasma, and the opaque kermesinus thrombus of lower floor is red blood cell.Skim tunica albuginea between red blood cell and blood plasma is leucocyte and blood platelet, accounts for 1% negligible.Can the concentration of glucose of practical measurement upper plasma layer and volume, full blood glucose concentration and volume, ask the concentration of lower floor's red blood cell layer glucose.Like the syrup of two glasss of variable concentrations, the concentration of the syrup of known one glass of high concentration and volume, also know two glasss of mixings after concentration and volume, also know the volume of low concentration syrup, ask the concentration of low concentration syrup.
This method plasma glucose concentration used, full blood glucose concentration all use same instrument, and German EKF diagnostic companies malaga sugar/lactic acid analysis instrument measures.
If 1ml anticoagulant heparin whole blood, we use German EKF diagnostic companies malaga sugar/lactic acid analysis instrument actually can record its plasma glucose concentration, full blood glucose concentration, then determine hematocrit value (HCT) with hydro-extractor
So:
Plasma glucose concentration × (1ml-1ml × hematocrit value)+mean corpuscular concentration of glucose × (1ml × hematocrit value)=full blood glucose concentration × 1ml
Mean corpuscular concentration of glucose=[full blood glucose concentration × 1ml-plasma glucose concentration × (1ml-1ml × hematocrit value)] ÷ (1ml × hematocrit value)
Can be reduced to:
Mean corpuscular concentration of glucose=[full blood glucose concentration-plasma concentration of glucose × (1-hematocrit value)] ÷ hematocrit value
The unit of mean corpuscular concentration of glucose and the full blood glucose concentration for calculating, plasma glucose concentration unit are consistent.
Such as: certain human blood sample anticoagulant heparin, we first gather whole blood mixing whole blood assay full blood glucose concentration and record 5.00mmol/L, a residual blood part measures hematocrit value and records 45%, and it is 5.70mmol/L that all the other centrifugal blood separated plasmas measure plasma glucose concentration.In order to reduce the impact of haemocyte metabolism on concentration of glucose, above three numerical value will complete in the shortest timing.Above numerical value substitutes into formula: this person's mean corpuscular concentration of glucose=[5.00mmol/L-5.70mmol/L × (1-0.45)] ÷ 0.45 ≈ 4.14
This person's mean corpuscular concentration of glucose is 4.14mmol/L.
Claims (1)
1. one kind measures the method for mean corpuscular concentration of glucose, it is characterized in that: utilize same sample to measure its plasma glucose concentration, full blood glucose concentration and hematocrit value, mean corpuscular concentration of glucose is calculated by these three measurement results, its formula is: mean corpuscular concentration of glucose=[full blood glucose concentration-plasma concentration of glucose × (1-hematocrit value)] ÷ hematocrit value, and the unit of mean corpuscular concentration of glucose and the full blood glucose concentration for calculating, plasma glucose concentration unit are consistent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410066276.XA CN103808774B (en) | 2014-02-26 | 2014-02-26 | Mean corpuscular concentration of glucose |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410066276.XA CN103808774B (en) | 2014-02-26 | 2014-02-26 | Mean corpuscular concentration of glucose |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103808774A CN103808774A (en) | 2014-05-21 |
CN103808774B true CN103808774B (en) | 2016-01-13 |
Family
ID=50705857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410066276.XA Expired - Fee Related CN103808774B (en) | 2014-02-26 | 2014-02-26 | Mean corpuscular concentration of glucose |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103808774B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11680925B2 (en) | 2014-11-25 | 2023-06-20 | Polymer Technology Systems, Inc. | Systems and methods for electrochemical hematocrit determination by alternate current impedance phase angle determinations |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1036079A (en) * | 1988-03-21 | 1989-10-04 | 罗伯特·A·利费恩 | Measure the method for haemoglobin |
WO1999012021A1 (en) * | 1997-08-29 | 1999-03-11 | Han Chi Neng Arthur | Analyte detection systems |
CN1605869A (en) * | 2003-10-09 | 2005-04-13 | 堀口升 | Blood examination method |
JP2005160782A (en) * | 2003-12-03 | 2005-06-23 | Hitachi Ltd | Blood sugar level measuring instrument |
CN102419367A (en) * | 2010-09-24 | 2012-04-18 | 株式会社堀场制作所 | Whole blood immunity measuring device and whole blood immunity measuring method |
-
2014
- 2014-02-26 CN CN201410066276.XA patent/CN103808774B/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1036079A (en) * | 1988-03-21 | 1989-10-04 | 罗伯特·A·利费恩 | Measure the method for haemoglobin |
WO1999012021A1 (en) * | 1997-08-29 | 1999-03-11 | Han Chi Neng Arthur | Analyte detection systems |
CN1605869A (en) * | 2003-10-09 | 2005-04-13 | 堀口升 | Blood examination method |
JP2005160782A (en) * | 2003-12-03 | 2005-06-23 | Hitachi Ltd | Blood sugar level measuring instrument |
CN102419367A (en) * | 2010-09-24 | 2012-04-18 | 株式会社堀场制作所 | Whole blood immunity measuring device and whole blood immunity measuring method |
Also Published As
Publication number | Publication date |
---|---|
CN103808774A (en) | 2014-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Trumpff et al. | Stress and circulating cell-free mitochondrial DNA: A systematic review of human studies, physiological considerations, and technical recommendations | |
Marlar et al. | Activated partial thromboplastin time monitoring of unfractionated heparin therapy: issues and recommendations | |
Piratelli et al. | Nutritional evaluation of stage 5 chronic kidney disease patients on dialysis | |
Anz et al. | Exercise-mobilized platelet-rich plasma: short-term exercise increases stem cell and platelet concentrations in platelet-rich plasma | |
CN103293250B (en) | Diabetic nephropathy diagnostic kit and application thereof | |
CN106645665B (en) | A kind of thrombin time detection reagent | |
CN102692511B (en) | Kit (Developing substrate method) for testing protein C (PC) | |
Spiezia et al. | More severe hypercoagulable state in acute COVID-19 pneumonia as compared with other pneumonia | |
Meenakshi | Effect of dialysis on certain biochemical parameters in chronic renal failure patients | |
CN105954239A (en) | Method for detecting platelet aggregation function | |
CN103808774B (en) | Mean corpuscular concentration of glucose | |
Ladenson et al. | Relationship of physical symptoms, ECG, free calcium, and other blood chemistries in reinfusion with citrated blood | |
Güvenc et al. | Comparison of mean platelet volume values among different causes of pulmonary hypertension | |
Lancé et al. | The effects of pneumatic tube system transport on ROTEM analysis and contact activation assessed by thrombin generation test | |
CN103926169B (en) | A kind of indirect determination method for mean corpuscular lactic acid concn | |
Salazar Vázquez et al. | Blood pressure directly correlates with blood viscosity in diabetes type 1 children but not in normals | |
Gyawali et al. | Hemorheological parameters better classify metabolic syndrome than novel cardiovascular risk factors and peripheral vascular disease marker | |
Szygula-Jurkiewicz et al. | Red blood cell distribution width in end-stage heart failure patients is independently associated with all-cause mortality after orthotopic heart transplantation | |
Katayama et al. | Determinants of blood rheology in healthy adults and children using the microchannel array flow analyzer | |
Liu et al. | Association between serum magnesium and blood count: Influence of type 2 diabetes and central obesity | |
Meex et al. | Analytical validation of the new plasma calibrated Accu-Chek® test strips (Roche Diagnostics) | |
Ehikhuemen Okonofua et al. | Polycythemia, Thrombocythemia, and Hyperfibrinogenemia are Associated With Streptozotocin-induced Diabetes and Salt-induced Hypertension in Male Wistar Rats | |
Wu et al. | YiqiHuoxue decoction and its ethanol precipitation show anti-platelet and antithrombotic effects by suppressing thromboxane B2 formation | |
Heizer et al. | Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life | |
CN108132284B (en) | A kind of test method of electrochemical sensor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160113 |